SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. Co. is focused on the development of novel therapeutics for a range of cancer indications. Co.'s product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. We show 31 historical shares outstanding datapoints in our coverage of SLS's shares outstanding history.
Understanding the changing numbers of SLS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SLS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SLS by allowing them to research SLS shares outstanding history
as well as any other stock in our coverage universe. |
Free SLS Email Alerts:
Video: Shares Outstanding Importance
